SMTI · Sanara MedTech Inc.

Sanara MedTech Inc. delivered a strong Q1 FY2026, achieving profitability with revenue growth and margin expansion offsetting prior-year losses. Revenue reached $27.8M, up 18.6% from $23.4M in Q1 FY2025, supported by net revenue growth factors as noted in management discussion. This topline acceleration directly fueled gross profit to $25.9M, a 19.8% increase from $21.6M, with gross margin expanding to 93.1%. Higher gross profit and margin stemmed primarily from the revenue growth and favorable product mix, enhancing scalability in the surgical-focused portfolio including recent BIASURGE access via the Vizient Innovative Technology contract effective January 1, 2026.

Operating leverage materialized as income swung to $2.6M from a -$2.1M loss, yielding a 9.5% operating margin. This shift underscores the benefits of revenue scale against operating costs, positioning the company on a clearer path to sustained profitability. Net income followed suit at $459K versus a -$3.5M prior-year loss, with diluted EPS at $0.05 compared to -$0.41. However, the bottom line faced pressure from elevated other expenses, driven by higher interest expense and fees on the CRG Term Loan alongside share of losses from equity method investments. These dynamics highlight the trade-off between growth investments and debt servicing costs.